Yongjiang Chen

This inventor holds 8 USPTO granted patents, plus 4 CIPO patents and 7 EPO patents. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Jiangsu Hengrui Co., Ltd.. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yongjiang Chen. Retrieved from https://idiyas.com/inventor/yongjiang-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8

% Patents Active = 37.5

CIPO Patents = 4

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 15(Granted Patents)

Company Filing History:

7 out of 159

Jiangsu Hengrui Medicine Company Ltd.

patents

1 out of 1

Jiangsu Hengrui Co., Ltd.

patent

Years Active: 2012-2018

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10150770 - Crystal form of bisulfate of JAK inhibitor and preparation method therefor (2018-12-11),

2. 10023577 - Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof (2018-07-17),

3. 9309226 - Crystalline form I of tyrosine kinase inhibitor dimaleate and preparation methods thereof (2016-04-12),

4. 8580997 - Process for preparing R-beta-amino phenylbutyric acid derivatives (2013-11-12),

5. 8541405 - Methods for the preparation of Ivabradine sulfate and form I crystal thereof (2013-09-24),

6. 8481763 - Preparation process of dronedarone and its salts (2013-07-09),

7. 8362256 - Salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide (2013-01-29),

8. 8198485 - Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane (2012-06-12),

Title: Yongjiang Chen: Innovator in JAK Inhibitor Development

Introduction

Yongjiang Chen is a prominent inventor based in Jiangsu, China, known for his significant contributions to the field of medicinal chemistry. He holds a total of eight patents, showcasing his innovative approach to drug development, particularly in the area of Janus Kinase (JAK) inhibitors.

Latest Patents

Among his latest patents is the "Crystal form of bisulfate of JAK inhibitor and preparation method therefor." This patent describes a crystal form I of a JAK inhibitor, specifically a compound with the formula (I). The preparation method involves crystallizing any crystal form or amorphous compound solid of formula (I) in a single organic solvent to obtain the form I crystal. This crystal form I exhibits excellent crystal stability and chemical stability, making it suitable for clinical treatment due to its low toxicity and minimal residual solvent content. Another notable patent is the "Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof." This patent details a type II crystal of the same JAK inhibitor and outlines a method for its preparation, emphasizing the good stability and low toxicity of the crystallization solvent used.

Career Highlights

Yongjiang Chen has worked with notable companies in the pharmaceutical industry, including Jiangsu Hengrui Medicine Company Ltd. and Jiangsu Hengrui Co., Ltd. His work in these organizations has significantly advanced the development of JAK inhibitors, contributing to innovative therapeutic solutions.

Collaborations

Throughout his career, Yongjiang has collaborated with esteemed colleagues such as Piaoyang Sun and Guaili Wu. These partnerships have fostered a collaborative environment that enhances the research and development of new medicinal compounds.

Conclusion

Yongjiang Chen's innovative work in the field of JAK inhibitors has led to significant advancements in medicinal chemistry. His contributions through patents and collaborations highlight his role as a key figure in the development of effective therapeutic agents.

Profile summary based on public USPTO records.